: Surgical treatment of craniopharyngioma often leads to a rapid and dramatic weight gain, leading to hypothalamic obesity. Treatment focused on the diet, physical activity, and different types of drugs have very often provided unsatisfactory results. To date, no data have been reported on hypothalamic obesity (HO) regarding the use of semaglutide, a novel type 1 receptor glucagon-like peptide-1 agonist, to limit body weight gain after surgical removal of a neoplasm, despite its already documented efficacy in obesity treatment. In this case report, we tested semaglutide in an 18-year-old patient with HO induced by a surgical intervention for craniopharyngioma. A very favorable treatment response was found in terms of body weight reduction and improvement in metabolic parameters. Our patient lost more than than 30 kg after only 6 months of therapy, which has never been reported before in the literature on HO.

Semaglutide for Treating Obesity Induced by Craniopharyngioma Resection: A Successful Case Study / Sciacovelli, Cristina; Moschione, Ginevra; Garelli, Silvia; Pagotto, Uberto. - In: JCEM CASE REPORTS. - ISSN 2755-1520. - ELETTRONICO. - 1:4(2023), pp. luad074.1-luad074.5. [10.1210/jcemcr/luad074]

Semaglutide for Treating Obesity Induced by Craniopharyngioma Resection: A Successful Case Study

Sciacovelli, Cristina;Moschione, Ginevra;Garelli, Silvia;Pagotto, Uberto
2023

Abstract

: Surgical treatment of craniopharyngioma often leads to a rapid and dramatic weight gain, leading to hypothalamic obesity. Treatment focused on the diet, physical activity, and different types of drugs have very often provided unsatisfactory results. To date, no data have been reported on hypothalamic obesity (HO) regarding the use of semaglutide, a novel type 1 receptor glucagon-like peptide-1 agonist, to limit body weight gain after surgical removal of a neoplasm, despite its already documented efficacy in obesity treatment. In this case report, we tested semaglutide in an 18-year-old patient with HO induced by a surgical intervention for craniopharyngioma. A very favorable treatment response was found in terms of body weight reduction and improvement in metabolic parameters. Our patient lost more than than 30 kg after only 6 months of therapy, which has never been reported before in the literature on HO.
2023
Semaglutide for Treating Obesity Induced by Craniopharyngioma Resection: A Successful Case Study / Sciacovelli, Cristina; Moschione, Ginevra; Garelli, Silvia; Pagotto, Uberto. - In: JCEM CASE REPORTS. - ISSN 2755-1520. - ELETTRONICO. - 1:4(2023), pp. luad074.1-luad074.5. [10.1210/jcemcr/luad074]
Sciacovelli, Cristina; Moschione, Ginevra; Garelli, Silvia; Pagotto, Uberto
File in questo prodotto:
File Dimensione Formato  
Sciacovelli JCEM 2023.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 240 kB
Formato Adobe PDF
240 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/963794
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact